In this issue
Despite combination prophylaxis with HBIG and NUCs transforming outcomes after liver transplantation for hepatitis B, some studies have suggested a shift to NUC monotherapy. Yet with HBV recurrence being closely linked to hepatocellular carcinoma recurrence, is this really the best approach?
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.
Latest articles
All articles


We’ve noticed you’re accessing
from North/South America.
from North/South America.